CanSino Biologics Inc.

SEHK:6185 주식 보고서

시가총액: HK$7.6b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CanSino Biologics 미래 성장

Future 기준 확인 5/6

CanSino Biologics (는) 각각 연간 124.6% 및 34.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 119.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.1% 로 예상됩니다.

주요 정보

124.6%

수익 성장률

119.3%

EPS 성장률

Biotechs 수익 성장33.7%
매출 성장률34.3%
향후 자기자본 수익률5.1%
애널리스트 커버리지

Low

마지막 업데이트29 Jun 2024

최근 미래 성장 업데이트

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20
Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07
The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06
Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07
Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

May 12
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Jan 09
Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Sep 16
CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Aug 31
Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Aug 29
Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13
Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01
Is CanSino Biologics (HKG:6185) Using Too Much Debt?

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15
We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11
CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

Dec 26
Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

수익 및 매출 성장 예측

SEHK:6185 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20261,7791572884554
12/31/20251,213-5-582165
12/31/2024860-286-345-2475
3/31/2024371-1,513-1,201-671N/A
12/31/2023357-1,483-1,519-908N/A
9/30/2023503-1,420-1,867-1,207N/A
6/30/2023431-1,763-2,339-1,375N/A
3/31/2023636-1,170-2,660-1,599N/A
12/31/20221,035-909-2,927-1,852N/A
9/30/20221,921106-1,733-587N/A
6/30/20222,868989-99268N/A
3/31/20224,3322,0503281,464N/A
12/31/20214,3001,9148472,050N/A
9/30/20213,1051,113181,065N/A
6/30/20212,082643-250531N/A
3/31/2021488-388-873-317N/A
12/31/202025-397-638-350N/A
9/30/20206-239-413-230N/A
6/30/20204-189-333-196N/A
3/31/20206-135-310-164N/A
12/31/20192-157-271-154N/A
9/30/20196-137-265-131N/A
6/30/201911-156-280-140N/A
3/31/20199-158-252-132N/A
12/31/20189-138-284-124N/A
12/31/20179-64N/A-56N/A
12/31/20168-50N/A-34N/A

애널리스트 미래 성장 예측

수입 대 저축률: 6185 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.2% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: 6185 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: 6185 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: 6185 의 수익(연간 34.3% ) Hong Kong 시장( 7.8% 보다 빠르게 성장할 것으로 예상됩니다. 7.8% 연간).

고성장 수익: 6185 의 수익(연간 34.3% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: 6185 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 5.1 %).


성장 기업 발견